The 2010–2020 National Natural Science Foundation of China: Radiation Therapy

Abstract

Objective

This study explains the application number and funding rate of oncology projects undertaken by the National Natural Science Foundation of China (NSFC), with focus on tumor radiotherapy-related research over the past 11 years.

Methods

A stratified analysis was carried out on the application and funding status of tumor radiotherapy studies in different NSFC project categories, different research areas, and different tumor types. Research areas that required specific focus, such as immunology-related radiotherapy, multimodality imaging and radiomics, and post-radiotherapy organ injury, were separately analyzed.

Results

The status and development trends of various related research fields were studied, and the research results were presented with the support of the NSFC, in order to provide reference for future applications and funding allocations.

Conclusion

The number of applications for funding increases every year. Although the total number of funded projects has also increased every year, the funding rate has decreased year by year. Projects on radiotherapy and immunization have been at the forefront in recent years, and the funding rate for these projects increases yearly.

Keywords

National Natural Science Foundation of China / radiation therapy / funding rate

References

[1] SvobodaE. Research round-up: Cancer diagnosis. Nature, 2020, 579(780): S20-S21

[2] ChenW, XiaC, ZhengR, et al.. Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment. Lancet Global Heal, 2019, 7(2): e257-e269

[3] WeiW, ZengH, ZhengR, et al.. Cancer registration in China and its role in cancer prevention and control. Lancet Oncol, 2020, 21(7): e342-e349

[4] KumarS, WarrellJ, LiS, et al.. Passenger Mutations in More Than 2,500 Cancer Genomes: Overall Molecular Functional Impact and Consequences. Cell, 2020, 180(5): 915-927.e16

[5] AgerBJ, WellsSM, GruhlJD, et al.. Stereotactic body radiotherapy versus percutaneous local tumor ablation for early-stage non-small cell lung cancer. Lung Cancer, 2019, 138: 6-12

[6] FraserI, LefresneS, ReganJ, et al.. Palliative thoracic radiotherapy near the end of life in lung cancer: A population-based analysis. Lung Cancer, 2019, 135: 97-103

[7] DumaN. Lung-cancer researchers and clinicians must pay more attention to women. Nature, 2020, 587: S13-S13

[8] Schmidt-HegemannN-S, StiefC, KimT-H, et al.. Outcome After PSMA PET/CT-Based Salvage Radiotherapy in Patients with Biochemical Recurrence After Radical Prostatectomy: A 2-Institution Retrospective Analysis. J Nucl Med, 2019, 60: 227-233

[9] TorreyEF, KnableMB, RushAJ, et al.. Using the NIH Research, Condition and Disease Categorization Database for research advocacy: Schizophrenia research at NIMH as an example. Plos One, 2020, 15: e0241062

[10] CroffR, GowenLK, LindauerA, et al.. Including older rural adults in research: Practical guidance for addressing the NIH Inclusion Across the Lifespan policy. J Clin Transl Sci, 2020, 4: 431-436

[11] LangstonRG, ZhaoEH, WongKH, et al.. Recent trends in NIH funding for top surgeon-scientists. Am J Surg, 2020, 222: 281-285

[12] WangSM, PfeifferRM, GierachGL, et al.. Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort. Breast Cancer Res, 2020, 22: 129

[13] WelchLC, Tomoaia-CotiselA, ChangH, et al.. Do common metrics add value? Perspectives from NIH Clinical and Translational Science Awards (CTSA) Consortium hubs. J Clin Transl Sci, 2020, 5: e68

[14] WelchLC, Tomoaia-CotiselA, NoubaryF, et al.. Evaluation of initial progress to implement Common Metrics across the NIH Clinical and Translational Science Awards (CTSA) Consortium. J Clin Transl Sci, 2020, 5: e25

[15] ZhangXB, YangSM. Viewing the current situation of pig model application in China’s medical field from the application and funding of NSFC. J Otology, 2020, 16: 34-39

[16] LuoHM, LiuXW, ZhangFZ, et al.. Analysis of projects funded by NSFC in field of efficacy material base of traditional Chinese medicine. China J Chin Materia Medica, 2020, 45: 3233-3237(Chinese)

[17] ChenL, XiaX, HeB, et al.. Analysis of projects funded by NSFC in field of processing Chinese materia medica in recent five years. China J Chin Materia Medica, 2015, 40: 1639-1643(Chinese)

[18] XuG, ZhangZ, LvQ, et al.. NSFC Health Research Funding and Burden of Disease in China. Plos One, 2014, 9(11): e111458